These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2093 related items for PubMed ID: 21406297

  • 1. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 2. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA.
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [Abstract] [Full Text] [Related]

  • 3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V, Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Spinella C, Gembillo G, Santoro D.
    Expert Opin Pharmacother; 2023 Nov; 24(15):1737-1746. PubMed ID: 37527180
    [Abstract] [Full Text] [Related]

  • 4. Management of phosphorus load in CKD patients.
    Taketani Y, Koiwa F, Yokoyama K.
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [Abstract] [Full Text] [Related]

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Mar; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 7. Use of phosphate binders in chronic kidney disease.
    Ketteler M, Biggar PH.
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [Abstract] [Full Text] [Related]

  • 8. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS.
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [Abstract] [Full Text] [Related]

  • 9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 10. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F.
    G Ital Nefrol; 2010 Feb; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [Abstract] [Full Text] [Related]

  • 11. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY, de Borst MH, Ter Wee PM, Vervloet MG, NIGRAM Consortium.
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [Abstract] [Full Text] [Related]

  • 12. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
    Ureña Torres PA.
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
    [Abstract] [Full Text] [Related]

  • 13. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D.
    J Nephrol; 2013 Apr; 26(6):993-1000. PubMed ID: 23543481
    [Abstract] [Full Text] [Related]

  • 14. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
    Hruska KA, Mathew S.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
    [Abstract] [Full Text] [Related]

  • 15. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
    Kestenbaum B.
    Semin Dial; 2007 Mar; 20(4):286-94. PubMed ID: 17635817
    [Abstract] [Full Text] [Related]

  • 16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG, Elisaf MS.
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [Abstract] [Full Text] [Related]

  • 17. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
    Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB.
    Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
    [Abstract] [Full Text] [Related]

  • 18. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
    Dhillon-Jhattu S, Sprague SM.
    Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
    [Abstract] [Full Text] [Related]

  • 19. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, Kramer HJ.
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [Abstract] [Full Text] [Related]

  • 20. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 105.